Digital Management of Early-Onset Type 2 Diabetes: Empowerment, Challenges, and Future Outlook

Clinical Snapshot

Key Findings

• P Value: Not applicable — no statistical testing conducted in this review

• Effect Size: Not quantified — narrative review; no pooled effect sizes reported. The characterisation 'modest improvements' is qualitative and not anchored to specific HbA1c reductions or time-in-range changes

• Primary Outcome: DHT demonstrated modest improvements in glycaemic control, weight management, and patient engagement in people with type 2 diabetes broadly; EOT2D-specific evidence is absent from the primary literature

• Nnt Or Sensitivity: Not calculable from this review. No NNT, sensitivity, specificity, or hazard ratio data are reported. Clinicians should refer to primary systematic reviews of individual DHT modalities (e.g., CGM in T2D, mHealth interventions) for quantitative estimates

• Confidence Interval: Not applicable — no meta-analytic synthesis performed

Clinical Application

DHT modalities discussed (CGM, mHealth apps, telemedicine) are increasingly available in clinical practice. However, feasibility is constrained by cost, interoperability with existing electronic health record systems, clinician digital health literacy, patient access to devices and data connectivity, and the absence of reimbursement frameworks for many DHT tools in most healthcare systems. Hybrid care models integrating DHT with in-person care are identified as the most pragmatic near-term approach. In Australia, CGM is PBS-subsidised for people with type 1 diabetes and selected type 2 diabetes populations (those on intensive insulin regimens), but reimbursement for EOT2D patients on non-insulin therapies remains limited. The TGA has approved several CGM devices and digital health platforms, but regulatory pathways for software-as-a-medical-device (SaMD) are still maturing. RACGP guidelines support shared decision-making around technology use in diabetes management but do not yet provide EOT2D-specific DHT recommendations. The My Health Record system and Medicare Benefits Schedule telehealth items (expanded post-COVID-19) provide infrastructure for some DHT integration. Digital health equity concerns are particularly salient for Aboriginal and Torres Strait Islander Australians and rural/remote populations with EOT2D, where digital divide risks are amplified. The Australian Digital Health Agency's National Digital Health Strategy 2023–2028 provides a policy framework within which EOT2D-specific DHT programs could be developed. Adults diagnosed with type 2 diabetes before age 40, particularly those with high digital literacy, complex lifestyle demands (employment, reproduction, psychosocial stressors), and long anticipated disease duration. The review's theoretical framework is most applicable to younger adults in urban, digitally connected settings.

Abstract

PURPOSE OF REVIEW: Early-onset type 2 diabetes (EOT2D), defined as a diabetes diagnosis before 40 years of age, is rising globally and associated with an aggressive disease course and early complications. This review examines the role of digital health technologies (DHT) in addressing the unique clinical and life-course challenges of EOT2D. RECENT FINDINGS: DHT, including continuous glucose monitoring, mobile health applications, digital therapeutics, telemedicine, remote patient monitoring, wearable devices, and artificial intelligence-based analytics, have demonstrated modest improvements in glycemic control, weight management, and patient engagement in people with type 2 diabetes. However, evidence in adults with EOT2D remains limited. Compared with usual-onset T2D, people with EOT2D may derive particular benefits due to higher digital literacy, greater lifestyle variability, and longer anticipated disease duration. Although DHT shows promise for improving empowerment and care integration in EOT2D, important gaps persist, including a lack of EOT2D-specific trials, digital divide-related inequities, interoperability challenges, and reimbursement barriers. Future research should prioritize tailored interventions and hybrid care models to optimize long-term outcomes in this high-risk population.

References

1. 1.Guo, L.-J., Low, K.-S., Tae, S.-K., & Lim, L.-L. (2026). Digital management of early-onset type 2 diabetes: Empowerment, challenges, and future outlook. Current Diabetes Reports. https://doi.org/10.2337/dc22-1099